{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 55,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a hierarchical testing strategy with alpha-exhaustive recycling and gatekeeping.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/24",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "callout",
      "text": "Study considered positive if either of the dual primary endpoints were met",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30d8e388-8ca9-4acc-a0ac-babe1efa58d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.53,
        "y": 0.21
      },
      "kind": "diagram",
      "text": "Flowchart showing 5% alpha split between pCR (0.1%) and EFS (4.9%), followed by sequential testing of OS and 5-year OS.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36211e2a-1cbd-4d90-a730-15216820e441",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "MTP with alpha-exhaustive recycling and gatekeeping strategy used across dual primary endpoints and then secondary endpoints of OS and 5-year OS. One pCR analysis was planned ~6 months after the last patient was randomised. In this planned interim analysis, the estimated number of events across the 2 arms was 410 for EFS and 288 for OS. The actual numbers of events were 433 for EFS and 305 for OS.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95f05e8b-3122-4d8f-9f32-338f0bdd53b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "NIAGARA was designed with a multiple testing procedure across key primary and secondary endpoints",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e36311c-4606-4822-bfce-084202d2f394",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "81be9c76-bb75-410c-8f60-3a38b06e85a2",
      "evidence": "diagram/process: Flowchart showing 5% alpha split between pCR (0.1%) and EFS (4.9%), followed by sequential testing of OS and 5-year OS.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "multiple-testing-procedure",
      "slug": null,
      "matchId": "9674c46e-3004-401e-aa66-f36227b8ed84",
      "evidence": "Diagram showing alpha-spending and gatekeeping logic",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 25,
      "from": 23,
      "beatId": "ee40693e-a830-4773-906c-580d23182958",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document presents the design and baseline characteristics of the NIAGARA trial.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e1d82b9f-ab34-4351-be54-5e9df327f1c4",
      "evidence": "The document highlights the high unmet need and presents NIAGARA as a solution.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet need in muscle-invasive bladder cancer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}